Sagimet Biosciences Announces Upcoming Panel Participation at Fierce Biotech Week

Company Overview - Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways [3] - The company is developing fatty acid synthase (FASN) inhibitors, with its lead drug candidate, denifanstat, being an oral, once-daily pill for treating metabolic dysfunction associated steatohepatitis (MASH) [3] - Denifanstat has received Breakthrough Therapy designation from the FDA for treating non-cirrhotic MASH with moderate to advanced liver fibrosis [3] Clinical Trials and Developments - The FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH has been successfully completed with positive results [3] - Sagimet has initiated a Phase 1 first-in-human clinical trial for a second oral FASN inhibitor, TVB-3567, which is planned for acne treatment in the U.S. [3] Upcoming Events - Sagimet will participate in a drug development panel at Fierce Biotech Week from October 7-9, 2025, in Boston, MA [1] - The panel titled "How Biotechs are Leveraging Artificial Intelligence (AI)/Machine Learning (ML) to Drive Efficiency and ROI" will feature Dr. Marie O'Farrell, Senior Vice President of Research and Development at Sagimet [2] - The discussion will focus on the application of AI in drug development, particularly how Sagimet employs AI-based digital pathology platforms to enhance clinical trials for MASH [2]